Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales?

• DOI: 10.33321/cdi.2021.45.12
• Publication Date: 2021-02-26T01:27:11Z
• Authors: Benjamin H Armstrong; Athena Limnios; David A Lewis; Tiffany Hogan; Ratan Kundu; Sanghamitra Ray; Masoud Shoushtari; Jasmin El Nasser; Tim Driscoll; Monica M Lahra
• Keywords: Neisseria gonorrhoeae

The key issues with Neisseria gonorrhoeae infections, in Australia and elsewhere, are coincident increases disease rates antimicrobial resistance (AMR), although these factors have not been shown to be correlated. Despite advances diagnosis, control of this remains elusive, incidence continues increase. Of the Australian jurisdictions, New South Wales (NSW) has highest N. notifications, over five-year period 2015-2019, notifications NSW increased above national average (by 116% versus 85%, respectively). Gonococcal is reliant on effective antibiotic regimens. However, escalating AMR a global health priority, as collateral injury untreated infections substantive impacts sexual newborn health. Currently, our first-line therapy for gonorrhoea also last line, no ideal alternative identified. some limitations, gentamicin licensed readily available Australia, proposed treatment resistant guidelines; however, supportive published microbiological data lacking. Analysis gonococcal patterns within 1991-2019, including 35,000 clinical isolates from NSW, illustrates establishment spread population-level all contemporaneous therapies. An analysis susceptibility 2,768 2015-2020, demonstrates that median minimum inhibitory concentration (MIC) remained low, at 4.0 mg/L, was detected any isolate. There demonstration MIC drift time (p = 0.91, Kruskal-Wallis test), nor differences distributions according patients' sex or site specimen collection. This first large-scale evaluation Australia. No isolates, hence likely an option NSW.